Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug
DOI: https://doi.org/10.2147/IJN.S402418
IF: 7.033
2023-03-30
International Journal of Nanomedicine
Abstract:Chaemin Lim, 1, &ast Yuseon Shin, 2, &ast Kioh Kang, 2 Patihul Husni, 2 Dayoon Lee, 2 Sehwa Lee, 2 Han-Gon Choi, 3 Eun Seong Lee, 4 Yu Seok Youn, 5 Kyung Taek Oh 1, 2 1 College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea; 2 Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul, 06974, Republic of Korea; 3 College of Pharmacy, Hanyang University, Ansan, 15588, South Korea; 4 Department of Biotechnology, The Catholic University of Korea, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea; 5 School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea &astThese authors contributed equally to this work Correspondence: Kyung Taek Oh, College of Pharmacy, Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul, 06974, Republic of Korea, Tel +82-2-824-5617, Email Introduction: Ligand-conjugated liposomes are promising for the treatment of specific receptor-overexpressing cancers. However, previous studies have shown inconsistent results because of the varying properties of the ligand, presence of a polyethylene glycol (PEG) coating on the liposome, length of the linker, and density of the ligand. Methods: Here, we prepared PEGylated liposomes using PEG-linkers of various lengths conjugated with folate and evaluated the effect of the PEG-linker length on the nanoparticle distribution and pharmacological efficacy of the encapsulated drug both in vitro and in vivo. Results: When folate was conjugated to the liposome surface, the cellular uptake efficiency in folate receptor overexpressed KB cells dramatically increased compared to that of the normal liposome. However, when comparing the effect of the PEG-linker length in vitro, no significant difference between the formulations was observed. In contrast, the level of tumor accumulation of particles in vivo significantly increased when the length of the PEG-linker was increased. The tumor size was reduced by > 40% in the Dox/FL-10K-treated group compared to that in the Dox/FL-2K- or 5K-treated groups. Discussion: Our study suggests that as the length of PEG-linker increases, the tumor-targeting ability can be enhanced under in vivo conditions, which can lead to an increase in the antitumor activity of the encapsulated drug. Graphical Keywords: PEGylated liposome, ligand-conjugated liposome, folate receptor, PEG-linker length Graphical Use of nanotechnology in cancer treatment has gained considerable interest in recent times for drug delivery. 1–4 Numerous researchers have employed nanotechnology to improve drug bioavailability and mitigate the toxicity and adverse effects associated with drugs. 5–7 In particular, various types of nano-sized drug-delivery systems, such as liposomes, nanogels, polymeric micelles, and lipid nanoparticles, have been developed to maximize drug efficacy by controlling drug release from tumor tissues. 8–12 Liposomes are the most commonly used drug-delivery systems. 13–18 They can encapsulate both hydrophilic and hydrophobic molecules and improve cellular uptake at the tumor site owing to enhanced permeability and retention (EPR). When liposomes are pegylated, they are often referred to as "stealth carriers" because the PEG coating reduces their recognition and clearance by the immune system. 19–21 Compared to small molecules, the liposome system offers various advantages such as self-assembly, biocompatibility, and favorable physicochemical properties that can change the properties of drugs. 15,22 An important feature of liposomes is that various functional groups can be introduced on their surfaces that provide an attractive scaffold. 23–25 However, liposomal nanoparticles lack selectivity for cancer cells. 26 To overcome this drawback, many researchers have used active targeting strategies by applying targeting ligands such as targeting molecules, antibodies, and peptides to the scaffolds. 27–31 Active targeting strategies not only enhance drug accumulation in cancer cells, but also diminish toxicity by reducing drug delivery to non-specific tissues. 15,32–34 However, active targeting strategies for nanoparticles have not always been successful. 23,35–37 For example, targeted liposomal nanoparticles may fail in their purpose because of differences in tumor model types and PEG coatings, linkers for conjugate targeting ligands, and differences in the properties of targeting ligands. 38,39 PEG on PEGylated lip -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology